Trials / Completed
CompletedNCT00909064
The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 114 (actual)
- Sponsor
- Paul Di Cesare,MD · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The investigators hypothesize that Arixtra patients will be less likely to experience wound infection than patients who have received low-molecular weight heparin, coumadin or aspirin with mechanical compression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fondaparinux Sodium (Arixtra) | 2.5 mg once per day to begin 6-8 hours after surgery and continued for 10 days. |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2009-05-27
- Last updated
- 2017-05-15
- Results posted
- 2017-05-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00909064. Inclusion in this directory is not an endorsement.